Using lung function tests to diagnose COPD can help patients and reduce healthcare costs
Patients with chronic obstructive pulmonary disease (COPD) would benefit if pulmonary function testing was used more consistently to diagnose the condition, according to a study in CMAJ.
COPD is the third leading cause of death worldwide and affects more than 10 per cent of adults. Testing airflow with pulmonary function testing is a key tool in diagnosing COPD, but it is underused, with only 30 per cent to 50 per cent of people with physician-diagnosed COPD undergoing testing.
“Given low rates of testing, these findings point to an opportunity to improve patient outcomes, reduce health services use and decrease healthcare costs by increasing rates of testing for suspected COPD,” writes Dr. Andrea Gershon, Sunnybrook Research Institute and Institute for Clinical Evaluative Sciences (ICES), with coauthors.
Researchers looked at data for 68 898 patients diagnosed with COPD between 2005 and 2012, including 16 798 patients with newly diagnosed COPD. Only 41% had received pulmonary function testing, and these patients were more likely to be younger, have seen a specialist and have a primary care physician who followed clinical guidelines for COPD. They were also less likely to have comorbidities.
The researchers found that patients who underwent lung function testing as a diagnostic tool were 10.4% less likely to be hospitalized for COPD or to die of any cause compared with patients who did not undergo testing when other differences between these groups were controlled for. They also found an association between lung function testing and increased use of medication for COPD, a finding consistent with previous research.
“Our results support the commonly held understanding that pulmonary function testing is key to the accurate diagnosis and quality care of people with COPD,” state the authors.
They suggest that using this testing more frequently to diagnosis suspected cases of COPD can improve patient outcomes, promote better use of healthcare services and cut costs.
The study was conducted by researchers at ICES, the Sunnybrook Health Sciences Centre, The Hospital for Sick Children (SickKids), the University Health Network and the Dalla Lana School of Public Health, University of Toronto, Toronto, Ontario; and the University of Ottawa, Ottawa, Ontario. It was supported by a grant from the Ontario Lung Association and Pfizer Canada.
The Institute for Clinical Evaluative Sciences (ICES) is an independent, non-profit organization that uses population-based health information to produce knowledge on a broad range of healthcare issues. Our unbiased evidence provides measures of health system performance, a clearer understanding of the shifting healthcare needs of Ontarians, and a stimulus for discussion of practical solutions to optimize scarce resources. ICES knowledge is highly regarded in Canada and abroad, and is widely used by government, hospitals, planners, and practitioners to make decisions about care delivery and to develop policy. For the latest ICES news, follow us on Twitter: @ICESOntario
FOR FURTHER INFORMATION PLEASE CONTACT:
Media Advisor, ICES
(o) 416-480-4780 or (c) 647-406-5996